



SUPPLEMENTARY INFORMATION CHAPTER 4

Survival proportions: Survival of Clearance T6 PFS




Survival proportions: Survival of Clearance T6 OS




Supplementary Figure 1. Clearance at T6, as determined by analyzing if mutant ctDNA levels of the *EGFR*ex20+ mutation were either present, absent (below the limit of detection), or reduced (>30%) at T6 in patients with detectable ctDNA at baseline of the *EGFR*ex20+ variant, was not significantly different in survival outcomes both in PFS (log-rank, $p=0.52$) and OS (log-rank, $p=0.54$) (S. Figure 3). Abbreviations: PFS = Progression Free Survival, OS = Overall Survival. T6 = week 6.

Survival proportions: Survival of PFS_detection EGFR baseline




Survival proportions: Survival of OS_detection EGFR baseline




Supplementary Figure 2. There was no difference in survival outcomes according to detection of the *EGFR*ex20+ mutation at baseline in terms of both PFS (log-rank, $p=0.41$) and OS (log-rank, $p=0.20$).

Survival proportions: Survival of PFS_mutation at progression




Survival proportions: Survival of OS_mutation at progression




Supplementary Figure 3. Patients with a variant potentially associated with treatment resistance at progression did not have a significant survival disadvantage in either PFS (log-rank, $p=0.20$) or OS (log-rank, $p=0.56$).

Survival proportions: Survival of PFS_detection EGFR amplification baseline




Survival proportions: Survival of OS_detection EGFR amplification baseline




Supplementary Figure 4. There was no difference in survival outcomes according to detection of the *EGFR* amplification at baseline in terms of both PFS (log-rank, $p=0.85$) and OS (log-rank, $p=0.69$).

Survival proportions: Survival of PFS_detection TP53 baseline



Survival proportions: Survival of OS_detection TP53 baseline



Supplementary Figure 5. There was no difference in survival outcomes according to detection of the TP53 mutation at baseline in terms of both PFS (log-rank, $p=0.37$) and OS (log-rank, $p=0.12$).